<DOC>
	<DOCNO>NCT01432938</DOCNO>
	<brief_summary>Warfarin commonly use drug prevent blood clotting . The purpose study determine dulaglutide ( LY2189265 ) affect warfarin work . The study involve two different treatment ( Treatment 1 : warfarin ; Treatment 2 : dulaglutide + warfarin ) separate minimum washout period 24 day . In Treatment 1 , participant receive 10 milligram ( mg ) warfarin Day 1 . In Treatment 2 , participant receive 1.5-mg dose dulaglutide ( LY2189265 ) injection Day 1 10 mg dose warfarin Day 3 . Participants randomly assign different treatment sequence . Participants Treatment Sequence A receive Treatment 1 Treatment 2 . Participants Treatment Sequence B receive Treatment 2 Treatment 1 .</brief_summary>
	<brief_title>A Study Effect Dulaglutide Action Warfarin Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>male participant female partner childbearing potential , partner pregnant breastfeeding , agree use reliable method contraception time first dose 3 month last dose investigational product , determine investigator . The method may one following : condom spermicidal agent male participant sterilization true abstinence ( line participant 's usual lifestyle choice ; withdrawal calendar method consider acceptable ) female participant childbearing potential postmenopausal undergone document hysterectomy ( total partial ) . Such participant require use contraception must test negative pregnancy time enrolment . Postmenopausal define least 1 year post cessation menses ( without alternative medical cause ) follicle stimulate hormone ( FSH ) â‰¥40 milliinternational unit per milliliter ( mIU/mL ) body mass index ( BMI ) 18.5 32.0 kilogram per meter square ( kg/m^2 ) , inclusive , screen clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator venous access sufficient allow blood sample reliable willing make available duration study willing follow study restriction give write informed consent approve Lilly ethical review board ( ERB ) govern site currently enrol , complete discontinue within last 30 day , clinical trial involve investigational product , concurrently enrol type medical research judge scientifically medically compatible study know allergy glucagonlikepeptide 1 ( GLP1 ) relate compound include dulaglutide warfarin , related compound , component either formulation person previously complete withdrawn study study investigate dulaglutide 3 month prior screen receive glucagonlike peptide incretin mimetics 3 month prior screen history presence significant bleeding disorder , hematemesis , melena , severe recurrent epistaxis , hemoptysis , hematuria , intracranial hemorrhage personal history , family history , current evidence bleeding disorder , coagulopathy , clinically significant history bleed complication surgical procedure , tooth extraction , nose gingival bleeding , spontaneous bleeding ( include bleed joint space ) personal family history polycystic kidney disease protein C S deficiency history major head trauma ( loss consciousness ) within past year minor head trauma ( without loss consciousness ) within last 3 month prior screen history plan undergo major surgery last 3 month prior screen show positive fecal occult blood test screen abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study abnormal blood pressure ( least 5 minute sit ) , opinion investigator , increase risk associate participate study history presence cardiovascular , respiratory , hepatic , renal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data history presence pancreatitis ( history chronic pancreatitis idiopathic acute pancreatitis ) gastrointestinal disorder , example relevant esophageal reflux gall bladder disease , gastrointestinal disease impact gastric empty ( GE ) ( , gastric bypass surgery , pyloric stenosis , exception appendectomy ) could aggravate GLP1 analog . Participants mild dyslipidemia , participant cholecystolithiasis ( removal gall stone ) and/or cholecystectomy ( removal gall bladder ) past , sequela , may include study discretion screen physician Show evidence significant active neuropsychiatric disease family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC regularly use know drug abuse and/or show positive finding urinary drug screen show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody show evidence hepatitis C and/or positive hepatitis C antibody show evidence hepatitis B and/or positive hepatitis B surface antigen woman positive pregnancy test woman lactate used intend use overthecounter medication acetaminophen within 7 day prior first dose warfarin dulaglutide prescription medication ( exception vitamin/mineral supplement and/or hormone replacement therapy [ HRT ] ) within 14 day prior dose . Aspirin nonsteroidal antiinflammatory drug take 2 week prior first dose occasion show intend use drug dietary supplement may affect warfarin coagulation within 14 day prior first dose warfarin dulaglutide conduct study use intend use drug inhibits induce cytochrome P450 ( CYP ) 1A2 , CYP2C9 , CYP2C19 , CYP3A4 within 14 day prior first dose warfarin dulaglutide conduct study donate blood 500 milliliter ( mL ) within month prior screening average weekly alcohol intake exceed 21 unit per week ( male age 65 ) 14 unit per week ( male 65 female ) , unwilling stop alcohol consumption 48 hour prior admission ( Day 1 first treatment period ) discharge ( 1 unit = 12 ounce [ oz ] 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) smoker international normalized ratio/prothrombin time ( INR/PT ) activate partial thromboplastin time ( aPTT ) normal reference range screen female menstruate consume grapefruit , cranberry , grapefruit cranberrycontaining product within 7 day prior first dose warfarin dulaglutide opinion investigator sponsor , unsuitable inclusion study medical condition , medical history take medication contraindicate within warfarin Product Information Leaflet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>